In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen's Incivo to outshine Merck's Victrelis after fast-tracked NICE yes

This article was originally published in Scrip

Executive Summary

Janssen-Cilag's hepatitis C treatment Incivo (telaprevir) looks set to join rival drug Merck & Co's Victrelis (boceprevir) as an NHS treatment option in England and Wales after NICE, the health technology appraisal institute, fast-tracked final draft guidance recommending the drug, just one week after it did the same for fellow protease inhibitor Victrelis. However, analysts expect that sales of Incivo will eventually outstrip sales of Victrelis in the UK, as they have in the US.

You may also be interested in...



England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.

The Netherlands Swaps Germany For Norway To Set Prices

The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC016636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel